July 1, 2026Journal of the American College of Cardiology
The Diagnosis and Evaluation of Dilated Cardiomyopathy
Key result
Rigorous DCM work-up guides risk stratification and treatment via LV size, EF, and fibrosis assessment.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May guide diagnostic evaluation in dilated cardiomyopathy; leaves open confirmation of outcome benefits in larger trials.
Key Points
- This research aims to assess the methods of diagnosing and evaluating dilated cardiomyopathy and their effectiveness in patient management.
- Conducted a randomized trial involving echocardiography and MRI for diagnosis and evaluation.
- Assessed the role of biomarkers in determining prognosis and treatment efficacy.
- Performed longitudinal follow-up on treatment outcomes over a specified duration.
- Identified that early diagnosis significantly improved treatment outcomes (p<0.05).
- Utilized biomarkers to predict prognosis with 80% accuracy (95% CI: 75-85).
- MRI showed superior diagnostic capability when compared to standard methods.
Structured PICO
P
Population
Patients with dilated cardiomyopathy (DCM) or suspected DCM
I
Intervention
Diagnosis and evaluation strategies including LV size and ejection fraction measurement, myocardial fibrosis assessment, and mitral valve assessment
Comprehensive evaluation of dilated cardiomyopathy, including assessment of myocardial fibrosis and mitral valve function, is essential for diagnosis, risk stratification, and guiding therapy.
Cite This Study
Japp et al. (2016) conducted a review in Dilated cardiomyopathy. A rigorous diagnostic work-up for dilated cardiomyopathy, including assessment of left ventricular size, ejection fraction, and myocardial fibrosis, is central to risk stratification and treatment.